Prevention of chronic respiratorydiseases in childhood and its impact             later in life               Nikos Papado...
The high burden of chronic respiratory           diseases (CRD)   www.who.int/respiratory/
Asthma starts early in life
The Melbourne cohortAm J Respir Crit Care Med. 2000 Dec;162(6):2177-81
Aim:To predict and prevent any     long-term effects
Understanding mechanisms               Papadopoulos et al. Allergy (2007)
Asthma starts with an infection   • In 140 children, 47 of which were hospitalized for RSV bronchiolitis.   • Asthma outco...
12 month follow-up: Persistence (>= 2   additional episodes of wheeze)                                    35           15 ...
Asthma is an allergic disease AllergenDendritic cell               IL-1                                MBP ECP            ...
Asthma persists in allergic children                        Illi et al. Lancet 2006
Mechanisms of interaction
Synergy between virus & allergen exposure in hospital admissions       25       20       15Risk       10        5        0...
The PreDicta hypothesis                  (Atopy & Infection        other risk       Infection     Asthma                  ...
Other contributors•   Weather•   Pollution•   Stress•   Tobacco smoke
How can we prevent childhood           CRD?    Early pharmacological treatment            Infection control           Alle...
Early treatment in school-age children                            12  Yearly change of FEV1 %                            1...
Intervention effects• No long-term effect in fluticasone-treated  childrenGuilbert et al. (2006) NEJM 354:19
J Allergy Clin Immunol 2010;126:256-62
Is a rhinovirus vaccine possible ?Niespodziana, Papadopoulos, Valenta et al. FASEB J 2012
Allergen avoidance• Only thorough allergen  avoidance may have results   – Allergen testing     required
Allergen-specific Immunotherapy may     prevent disease progression              Jacobsen et al. Allergy 62:943-948.
Effects of passive exposure to ETS                                                                     Doctor             ...
Conclusions• Chronic respiratory diseases, including  asthma, place a high burden on public health• Asthma, the most frequ...
Conclusions• Early treatment, allergen avoidance, infection  control and environmental tobacco avoidance  may alleviate th...
Call for actionPublic Health:  1. Facilitate allergen immunotherapy      • Awareness campaigns      • Monitoring      • Up...
Prevention of Chronic Respiratory Diseases in Childhood and its Impact Later in Life
Prevention of Chronic Respiratory Diseases in Childhood and its Impact Later in Life
Prevention of Chronic Respiratory Diseases in Childhood and its Impact Later in Life
Upcoming SlideShare
Loading in...5
×

Prevention of Chronic Respiratory Diseases in Childhood and its Impact Later in Life

930

Published on

GRF One Health Summit 2012, Davos: Presentation by Prof. Nikos Papadopoulos - Secretary General - European Academy of Allergy Clinical Immunology EAACI

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
930
On Slideshare
0
From Embeds
0
Number of Embeds
3
Actions
Shares
0
Downloads
0
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide
  • 1. ston 1o xrono follow up 5/52 controls emfanisan vrogxiolitida gia thn opoia noshleuthkan - oi 3/5 htan RV positive2. persistence of wheeze thewrhsame oti parathroume se paidia pou parousiasan 2 or kai perissotera epeisodia syrigmou pou ta enoxlouse se tetoio vathmo wste na xreiastoun na epikoinwnhsoun h na episkeftoun ton paidiatro tous ( ta enoxlouse ston ypno, sto paixnidi, sto faghto )- h farmakeutikh agwgh den htan krithrio gia to an ypotropiasan h oxi- wstoso, ola phran farmakeutikh agwgh (toulaxiston gia 5 hmeres)
  • 10-year follow-up of the PAT studyThe percentage of children with and without asthma 7 years after termination (10-year follow-up) of specific immunotherapy. Based on the patients without asthma before treatment (n = 117). The absolute number of children is shown above the bars.Background: 3-year subcutaneous specific immunotherapy (SIT) in children withseasonal allergic rhinoconjunctivitis reduced the risk of developing asthmaduring treatment and 2 years after discontinuation of SIT (5-year follow-up)indicating long-term preventive effect of SIT.Objective: We evaluated the long-term clinical effect and the preventive effect ofdeveloping asthma 7-years after termination of SIT.Methods: One hundred and forty-seven subjects, aged 16–25 years with grassand/or birch pollen allergy was investigated 10 years after initiation of a 3-yearcourse of SIT with standardized allergen extracts of grass and/or birch or no SITrespectively. Conjunctival provocations were performed outside the season andmethacholine bronchial provocations were performed during the season andwinter. Asthma was assessed by clinical evaluation.Results: The significant improvements in rhinoconjunctivitis and conjunctivalsensitivity persisted at the 10-year follow-up. Significantly less actively treatedsubjects had developed asthma at 10-year follow-up as evaluated by clinicalsymptoms [odds ratio 2.5 (1.1–5.9)]. Patients who developed asthma amongcontrols were 24/53 and in the SIT group 16/64. The longitudinal treatmenteffect when adjusted for bronchial hyper-responsiveness and asthma status atbaseline including all observations at 3, 5 and 10 years follow-up (children withor without asthma at baseline, n = 189; 511 observations) was statisticallysignificant (P = 0.0075). The odds ratio for no-asthma was 4.6 95% CI (1.5–13.7) in favor of SIT.Conclusion: A 3-year course of SIT with standardized allergen extracts hasshown long-term clinical effects and the potential of preventing developmentof asthma in children with allergic rhinoconjunctivitis up to 7 years aftertreatment.Clinical implication: Specific immunotherapy has long-term clinical effects andthe potential of preventing development of asthma in children with allergic rhinoconjunctivitis up to 7 years after treatment termination.
  • Background: Environmental tobacco smoke (ETS) is a significant risk factor for the presence and increased severity of asthma and allergy-related symptoms in children. Smoking during pregnancy has detrimental effects on asthma-associated outcomes in childhood. Whether passive exposure of pregnant women to ETS may also lead to asthma in their offspring, is not known. The aim of our study was to investigate the association of passive exposure of pregnant women to ETS and asthma and / or allergy-related symptoms in preschool children.Methods: Cross-sectional data were collected with questionnaires from 2374 preschool children, recruited from public and private nurseries and day-care centres.Results: Parental smoking was significantly associated with wheezing symptoms in their children. Mother’s active smoking during pregnancy, significantly increased the risk for occurrence of asthma symptoms and /or medically diagnosed asthma in preschool children in a dose – dependent manner. Passive exposure to ETS, mainly during the 3rd trimester of pregnancy, was significantly associated with asthma and allergy – related symptoms after adjusting for several confounders in a multivariate analysis (current wheeze: OR=1.42, 95%CI=1.06-1.91, pruritic rash ever: OR= 1.45, 95%CI= 1.01-2.08).Conclusions: Passive exposure of pregnant women to ETS during the 3rd trimester is positively associated with asthma and allergy-related symptoms in their preschool age children. Public health policies should be oriented not only towards smoking cessation but also reinforce elimination of ETS exposure of pregnant women. 
  • Prevention of Chronic Respiratory Diseases in Childhood and its Impact Later in Life

    1. 1. Prevention of chronic respiratorydiseases in childhood and its impact later in life Nikos PapadopoulosAllergy Dpt, 2nd Pediatric Clinic,University of Athens, EAACI Secretary General
    2. 2. The high burden of chronic respiratory diseases (CRD) www.who.int/respiratory/
    3. 3. Asthma starts early in life
    4. 4. The Melbourne cohortAm J Respir Crit Care Med. 2000 Dec;162(6):2177-81
    5. 5. Aim:To predict and prevent any long-term effects
    6. 6. Understanding mechanisms Papadopoulos et al. Allergy (2007)
    7. 7. Asthma starts with an infection • In 140 children, 47 of which were hospitalized for RSV bronchiolitis. • Asthma outcome at 7.5 years higher in cases 35 30% 30Children with 25 asthma at age 207.5 years 15 (%) 10 5 3% 0 RSV Control (n=47) (n=93) Sigurs N et al. Am J Respir Crit Care Med 2000;161:1501-1507
    8. 8. 12 month follow-up: Persistence (>= 2 additional episodes of wheeze) 35 15 (42%) RSV (+) Relapses 64 24 21 (87%) Bronchiolitis cases RV (+) Relapses 5 5 (100%) RSV-RV(+) Relapses Controls: 5/52 (9.6%)Papadopoulos et al. unpublished 3/5 were RV(+)
    9. 9. Asthma is an allergic disease AllergenDendritic cell IL-1 MBP ECP LTs IgE PGs Th0-cell PAF B-cell Eosinophil Mast cell IL-4 IL-13 IL-10 Eotaxin IL-5 RANTES IFN- histamin Th1-cell Th2-cell VCAM-1 ICAM-1 E- selectin Systemic circulation
    10. 10. Asthma persists in allergic children Illi et al. Lancet 2006
    11. 11. Mechanisms of interaction
    12. 12. Synergy between virus & allergen exposure in hospital admissions 25 20 15Risk 10 5 0 Murray et al. Thorax (2005)
    13. 13. The PreDicta hypothesis (Atopy & Infection other risk Infection Asthma factors) ‘Blocked’ state Possibly Increased Repeated bronchiolitis susceptibility of events hyperreactivitywww.predicta.eu
    14. 14. Other contributors• Weather• Pollution• Stress• Tobacco smoke
    15. 15. How can we prevent childhood CRD? Early pharmacological treatment Infection control Allergen avoidance ETS avoidance
    16. 16. Early treatment in school-age children 12 Yearly change of FEV1 % 10 P = 0.02 8 6 4 2 0 <2 2–3 3–5 >5 Asthma duration at the beginning of therapy with budesonide Agertoft and Pedersen, Respir Med 1994
    17. 17. Intervention effects• No long-term effect in fluticasone-treated childrenGuilbert et al. (2006) NEJM 354:19
    18. 18. J Allergy Clin Immunol 2010;126:256-62
    19. 19. Is a rhinovirus vaccine possible ?Niespodziana, Papadopoulos, Valenta et al. FASEB J 2012
    20. 20. Allergen avoidance• Only thorough allergen avoidance may have results – Allergen testing required
    21. 21. Allergen-specific Immunotherapy may prevent disease progression Jacobsen et al. Allergy 62:943-948.
    22. 22. Effects of passive exposure to ETS Doctor Current diagnosed Ever wheeze wheeze asthma 1.31 ** 1.21 Either parent smoking 1.53 ** Father current smoker 1.21# 1.16 1.50 * mother current smoker 1.26 * 1.18 1.24 Active smoking during pregnancy 1.55 ** 1.40 ** 1.56* passive exposure to ETS during pregnancy 1.22 # 1.31 * 1.36 #Xepapadaki, Papadopoulos et al. Ped Allergy Immunol 2009
    23. 23. Conclusions• Chronic respiratory diseases, including asthma, place a high burden on public health• Asthma, the most frequent chronic disease in children, starts early in life, with a respiratory infection• Interactions between allergy and infection lead to chronic persistent disease
    24. 24. Conclusions• Early treatment, allergen avoidance, infection control and environmental tobacco avoidance may alleviate the long-term impact• Allergen-specific immunotherapy may prevent disease progression
    25. 25. Call for actionPublic Health: 1. Facilitate allergen immunotherapy • Awareness campaigns • Monitoring • Updating of National healthcare policies 2. Drastically reduce ETS exposureResearch: 3. Focus on infection-related consequences

    ×